Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient

Joshua A Hill, Chaitra S Ujjani, Alexander L Greninger, Mazyar Shadman, Ajay K Gopal, Joshua A Hill, Chaitra S Ujjani, Alexander L Greninger, Mazyar Shadman, Ajay K Gopal

No abstract available

Keywords: COVID-19; SARS-CoV-2; booster; hematologic malignancy; vaccine.

Conflict of interest statement

Declaration of interests J.A.H. received consulting fees from Gilead Sciences, Amplyx, Allovir, Allogene therapeutics, CRISPR therapeutics, and Takeda and research funding from Takeda, Allovir, Karius, and Gilead Sciences. C.S.U reports consulting fees from Atara, AstraZeneca, Epizyme, Abbvie, PYC, Genentech, ACDT, and TG therapeutics and research funding from loxo, PYC, AstraZeneca, and Adaptive Biotechnologies. A.L.G reports central testing contracts from Abbott, research grants from Gilead and Merck, and spouse’s salary from LabCorp. M.S reports consulting, advisory boards, steering committees, or data safety monitoring committees for Abbvie, Genentech, AstraZeneca, Sound Biologics, Pharmacyclics, Beigene, Bristol Myers Squibb, Morphosys, TG Therapeutics, Innate Pharma, Kite Pharma, Adaptive Biotechnologies, Epizyme, Eli Lilly, and Atara Biotherapeutics and research funding from Mustang Bio, Celgene, Bristol Myers Squibb, Pharmacyclics, Gilead, Genentech, Abbvie, TG Therapeutics, Beigene, AstraZeneca, Sunesis, Atara Biotherapeutics, and GenMab. A.K.G reports research funding from Seagen, Bristol Myers Squibb, Pharmacyclics, Gilead, Genentech, AstraZeneca, Pfizer, Teva, Takeda, Acrotec, IgM, I-Mab, Agios, and Merck and honoraria and/or consulting fees from Abbvie, Genentech, janssen, AstraZeneca, Pharmacyclics, Bristol Myers Squibb, Amgen, Morphosys, TG Therapeutics, Kite Pharma, Adaptive, SeaGen, Epizyme, Kite, Gilead, ADCT, Incyte, Karyopharm, Actinium, Asana bio, Nurix, and Aptevo.

References

    1. Addeo A., Shah P.K., Bordry N., Hudson R.D., Albracht B., Di Marco M., Kaklamani V., Dietrich P.-Y., Taylor B.S., Simand P.-F., et al. Immunogenicity of SARS-CoV-2 messenger RNA Vaccines in Patients with Cancer. Cancer Cell. 2021;39:1091–1098.
    1. Bradley B.T., Bryan A., Fink S.L., Goecker E.A., Roychoudhury P., Huang M.-L., Zhu H., Chaudhary A., Madarampalli B., Lu J.Y.C., et al. MedRxiv; 2021. Anti-SARS-CoV-2 antibody levels are concordant across multiple platforms but are not fully predictive of sterilizing immunity.
    1. Cardell K., Åkerlind B., Sällberg M., Frydén A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J. Infect. Dis. 2008;198:299–304.
    1. Crawford K.H.D., Eguia R., Dingens A.S., Loes A.N., Malone K.D., Wolf C.R., Chu H.Y., Tortorici M.A., Veesler D., Murphy M., et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses. 2020;12:E513.
    1. Herishanu Y., Avivi I., Aharon A., Shefer G., Levi S., Bronstein Y., Morales M., Ziv T., Shorer Arbel Y., Scarfò L., et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165–3173.
    1. Hillus D., Schwarz T., Tober-Lau P., Hastor H., Thibeault C., Kasper S., Helbig E.T., Lippert L.J., Tscheak P., Luisa Schmidt M., et al. MedRxiv; 2021. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study.
    1. Mato A.R., Roeker L.E., Lamanna N., Allan J.N., Leslie L., Pagel J.M., Patel K., Osterborg A., Wojenski D., Kamdar M., et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136:1134–1143.
    1. Pleyer C., Ali M.A., Cohen J.I., Tian X., Soto S., Ahn I.E., Gaglione E.M., Nierman P., Marti G.E., Hesdorffer C., et al. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood. 2021;137:185–189.
    1. Thakkar A., Gonzalez-Lugo J.D., Goradia N., Gali R., Shapiro L.C., Pradhan K., Rahman S., Kim S.Y., Ko B., Sica R.A., et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39:1081–1090. S1535-6108(21)00285-3.
    1. Werbel W.A., Boyarsky B.J., Ou M.T., Massie A.B., Tobian A.A.R., Garonzik-Wang J.M., Segev D.L. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Ann. Intern. Med. 2021 doi: 10.7326/L21-0282.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi